Search

Search Results

• PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA

  Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Stefan Hohaus

  e2014053

  2014-07-04

  https://doi.org/10.4084/mjhid.2014.053

  3212

  PDF: 1919

  HTML: 7455

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3454

  PDF: 2356

  HTML: 1412

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3682

  PDF: 1032

  HTML: 1859

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1631

  PDF: 1613

  HTML: 753

• HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?

  Antoine Thyss, Esma Saada, Lauris Gastaud, Frédéric Peyrade, Daniel Ré

  e2014050

  2014-07-01

  https://doi.org/10.4084/mjhid.2014.050

  2830

  PDF: 1315

  HTML: 3552

  Untitled: 178

  Untitled: 187

  Untitled: 166

• CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA

  Luca Castagna, Carmelo Carlo-Stella, Rita Mazza, Armando Santoro

  e2015015

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.015

  2735

  PDF: 1383

  HTML: 4597

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4340

  PDF: 1589

  HTML: 3438

  Tables and Images: 201

• EBV AND HIV-RELATED LYMPHOMA

  Michele Bibas, Andrea Antinori

  e2009032

  2009-12-29

  https://doi.org/10.4084/mjhid.2009.032

  1474

  PDF: 612

  HTML: 6794

• EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN

  Massimiliano Salati, Marina Cesaretti, Matteo Macchia, Mufid El Mistiri, Massimo Federico

  e2014048

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.048

  3451

  PDF: 1139

  HTML: 4976

  Incidence age-standardized rates for HL across the Mediterranean basin: 180

• ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY

  Eldad J Dann

  e2014063

  2014-09-05

  https://doi.org/10.4084/mjhid.2014.063

  2091

  PDF: 1301

  HTML: 3487

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1607

  PDF: 577

  HTML: 13912

• FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.

  Andrea Gallamini, Anna Borra

  e2017029

  2017-04-15

  https://doi.org/10.4084/mjhid.2017.029

  3256

  PDF: 1210

  HTML: 2177

• THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA

  Umberto Ricardi, Andrea Riccardo Filippi, Cristina Piva, Pierfrancesco Franco

  e2014035

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.035

  2164

  PDF: 921

  HTML: 6769

  Figure 1: 157

• ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Angelo Michele Carella

  e2012059

  2012-10-02

  https://doi.org/10.4084/mjhid.2012.059

  1975

  PDF: 771

  HTML: 1026

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3318

  PDF: 1250

  HTML: 2195

  Fi.1 Gritti.Rambaldi: 191

• IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE

  Francesco Di Raimondo, Giorgio La Nasa

  e2014039

  2014-05-29

  https://doi.org/10.4084/mjhid.2014.039

  2177

  PDF: 932

  HTML: 1871

• Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India

  Mary Theresa Sylvia, Biswajit Dey, Debdatta Basu, Sajini Elizabeth Jacob, Rakhee Kar, Biswajit Dubashi

  e2016060

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.060

  3135

  PDF: 750

  HTML: 2917

  Figure 1a and 1b: 136

  Figure 2: 142

  Figure 3: 164

  Figure 4: 143

  Figure 5: 148

  Tables 1-5: 141

• THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS

  Alessia Bari, Luigi Marcheselli, Raffaella Marcheselli, Eliana Valentina Liardo, Samantha Pozzi, Stefano Sacchi

  e2011065

  2011-12-20

  https://doi.org/10.4084/mjhid.2011.065

  2528

  PDF: 712

  HTML: 2283

• OUTCOME AND TOXICITY PATTERNS IN CHILDREN AND ADOLESCENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

  Paola Angelini, Laura Rodriguez, Mohammed Zolaly, Ahmed Naqvi, Sheila Weitzman, oussama Abla, Angela Punnett

  e2018020

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.020

  2807

  PDF: 796

  HTML: 361

• LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.

  Andrea Riccardo Filippi

  e2016041

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.041

  3660

  PDF: 1056

  HTML: 2263

  Figure 1: 196

• TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY

  Agustin Avilès, Maria-Jesus Nambo, Natividad Neri

  e2018006

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.006

  3492

  PDF: 1038

  HTML: 867

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1958

  PDF: 1079

  HTML: 168

• Prognostic Impact Of Baseline Immunologic Profile In Aggressive B-cell Non-Hodgkin’s Lymphomas

  Safaa M. Ramadan

  e2021018

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.018

  1051

  PDF: 344

  HTML: 224

• HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

  Michele Bibas, Gianluigi Biava, Andrea Antinori

  e2011030

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.030

  3802

  PDF: 1436

  HTML: 8488

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  1967

  PDF: 785

  HTML: 197

• IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy

  İbrahim Halil Açar, Sebnem Izmir Güner , Muzeyyen Aslaner Ak, Mesut Gocer, Erman Ozturk , Figen Atalay, Gulden Sincan , Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince, Emine Gulturk , Nazli Demir, Ali Dogan, Yildiz Ipek, Birol Guvenc

  e2022074

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.074

  1381

  PDF: 733

  HTML: 192

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  1901

  PDF: 843

  HTML: 1291

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2410

  PDF: 762

  HTML: 1722

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1262

  PDF: 783

  HTML: 115

• The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients

  Shuku Sato

  e2025070

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.070

  943

  PDF: 347

  HTML: 80

• BACTERIAL INFECTIONS FOLLOWING SPLENECTOMY FOR MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES

  Giuseppe Leone, Eligio Pizzigallo

  e2015057

  2015-10-12

  https://doi.org/10.4084/mjhid.2015.057

  4754

  PDF: 1928

  HTML: 8278

• EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS

  Ola Khorshid, Safaa M. Ramadan

  e2015058

  2015-10-16

  https://doi.org/10.4084/mjhid.2015.058

  1959

  PDF: 1034

  HTML: 1184

• EBV CHRONIC INFECTIONS

  Eligio Pizzigallo, Delia Racciatti, Valeria Gorgoretti

  e2010022

  2010-08-09

  https://doi.org/10.4084/mjhid.2010.022

  3386

  PDF: 1540

  HTML: 7777

• LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML

  Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles

  e2020020

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.020

  1616

  PDF: 1135

  HTML: 231

• EVOLVING DISEASE SPECTRUM AND CHARACTERISTICS OF PEOPLE WITH HIV IN EASTERN CHINA: A 12-YEAR STUDY

  Ye Xiong, Bohao Dai, Dairong Xiang, Jean-Pierre Routy, Biao Zhu

  e2025077

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.077

  351

  PDF: 171

  Html: 39

• Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

  Giovanni Manfredi Assanto ,, Matteo Totaro , Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, Giuseppe Gentile

  e2023061

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.061

  735

  PDF: 393

  HTML: 102

• INVASIVE CANDIDA INFECTIONS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: CURRENT EPIDEMIOLOGY AND THERAPEUTIC OPTIONS.

  Corrado Girmenia, Erica Finolezzi, Vincenzo Federico

  e2011013

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.013

  2218

  PDF: 942

  HTML: 1845

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2202

  PDF: 906

  HTML: 2350

• MOLECULAR CHARACTERIZATION OF EPSTEIN - BARR VIRUS BASED ON EBNA3C PROTEIN AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS IN JORDAN

  Rabaa Athamneh, Hiba Swaity, Waleed Almomani, Hayyan. Taweil , Assia Benbraiek, Anas Khalifeh

  e2025032

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.032

  761

  PDF: 716

  HTML: 97

• Very late onset Post-Transplantation Lymphoproliferative Disorder (PTLD) after haematopoietic stem cell transplant (HCT) – A Clinical Case

  Sharon Lionel, Liron Barnea Slonim, Guy Hannah, Victoria Potter, Daniele Avenoso

  e2024048

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.048

  976

  PDF: 949

  HTML: 141